Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-squamous non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your cancer must have a specific EGFR mutation (exon 19 deletion or exon 21 L858R) confirmed by a DNA test.
- You must be able to provide a sample of your tumor tissue for testing a marker called c-Met.
- You should be in good enough health to be up and about (ECOG score 0 or 1).
- You cannot have had prior treatment with an EGFR-targeted pill like osimertinib for advanced disease, unless it was used after surgery and more than 12 months ago.
- You must not have a history of lung scarring or inflammation (interstitial lung disease) that required steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
This study tests a new drug called telisotuzumab adizutecan against the usual treatments for people with a type of lung cancer that has spread and has not responded to previous therapy. It may be an option if your cancer has a specific marker and you have not had certain other conditions.
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.